NYSE American - Delayed Quote USD

Stereotaxis, Inc. (STXS)

2.1100

-0.0600

(-2.76%)

At close: June 13 at 4:00:00 PM EDT

Stereotaxis Inc (STXS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst ...

Stereotaxis Inc (STXS) reports a 9% revenue increase and European approval for its Magic catheter, while navigating headwinds and market uncertainties.

GuruFocus.com last month

STXS
-2.76%
Stereotaxis Inc. (STXS) Reports Q1 Loss, Tops Revenue Estimates

Stereotaxis (STXS) delivered earnings and revenue surprises of 0% and 6.74%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

STXS
-2.76%
Stereotaxis Reports 2025 First Quarter Financial Results

ST. LOUIS, May 12, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the first quarter ended March 31, 2025. “We’ve started the year with solid execution on key commercial and innovation efforts,” said David Fischel, Chairman and CEO. “This is a milestone rich year in which we are beginning to demonstrate the tangible reality and commercial impact of our compre

GlobeNewswire last month

STXS
-2.76%
AxoGen (AXGN) Reports Q1 Loss, Tops Revenue Estimates

AxoGen (AXGN) delivered earnings and revenue surprises of -100% and 0.61%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

AXGN

STXS
-2.76%
Thermo Fisher Scientific (TMO) Q1 Earnings and Revenues Beat Estimates

Thermo Fisher (TMO) delivered earnings and revenue surprises of 0.98% and 1.11%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

TMO

STXS
-2.76%
Stereotaxis to Report First Quarter 2025 Financial Results on May 12, 2025

ST. LOUIS, April 22, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2025 first quarter on Monday, May 12, 2025 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. EST that day to discuss the Company’s results and corporate developments. What:Stereotaxis first quarter 2025 fina

GlobeNewswire last month

STXS
-2.76%
Stereotaxis to Feature First-Ever Live Demo of GenesisX Robotic System at HRS 2025

GenesisX pairs clinical capability with broad accessibility in surgical roboticsST. LOUIS, April 21, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, announced today it will host a live demonstration of the GenesisX Robotic System at this year’s Heart Rhythm Symposium (HRS), taking place April 24 – 27 in San Diego, CA. This marks the first live, public demonstration of GenesisX, offering a glimps

GlobeNewswire last month

STXS
-2.76%
3 Promising Surgical Robotics Stocks to Keep an Eye on in 2025

Investing in surgical robotics stocks like ISRG, ZBH and STXS can be profitable for investors in 2025.

Zacks 2 months ago

ZBH

STXS
-2.76%
Nvidia’s Support Boosts Stereotaxis (STXS) in Advancing Robotic Surgery

We recently compiled a list of the Top 8 AI News Updates Investors Shouldn’t Miss. In this article, we are going to take a look at where Stereotaxis, Inc. (NYSEAMERICAN:STXS) stands against the other AI stocks. On March 19th, the stock market bounced back after the US Federal Reserve kept interest rates unchanged at 4.25% […]

Insider Monkey 2 months ago

STXS
-2.76%

NVDA
Stereotaxis Jumps 15% on NVIDIA's AI-Driven Collaboration: Is It a Buy Now?

The collaboration, highlighted at NVIDIA's GTC conference, aims to integrate artificial intelligence into surgical robotics, potentially enhancing Stereotaxis' technological capabilities.

Zacks 2 months ago

STXS
-2.76%

NVDA
March 2025 Penny Stocks With Promising Prospects

As the U.S. stock market navigates mixed trading sessions and economic uncertainties, investors are keenly watching for opportunities that can offer both value and growth potential. Penny stocks, though an older term, continue to represent smaller or less-established companies that may present attractive prospects for those willing to explore beyond the major indices. By focusing on penny stocks with strong financials and clear growth paths, investors might uncover promising opportunities in...

Simply Wall St. 2 months ago

AEVA

AEVAW

MYPS
Stereotaxis Highlighted by NVIDIA at GTC Artificial Intelligence Conference and Accepted into NVIDIA Connect Program

ST. LOUIS, March 19, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that NVIDIA highlighted Stereotaxis’ technology at NVIDIA GTC and has accepted Stereotaxis into the NVIDIA Connect program. NVIDIA GTC (GPU Technology Conference) is a global artificial intelligence (AI) conference that brings together engineers, researchers, and inventors working to pioneer applications for AI.

GlobeNewswire 2 months ago

STXS
-2.76%
Stereotaxis to Present at 37th Annual Roth Conference

ST. LOUIS, March 10, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fischel, Chairman and CEO, will participate in the 37th Annual ROTH Conference in Dana Point, California. Mr. Fischel will be available for one-on-one meetings on Monday, March 17th, 2025. “We appreciate the opportunity to participate in the Roth Conference and to share Stereotaxis’ differentiated tec

GlobeNewswire 3 months ago

STXS
-2.76%
Stereotaxis Stock Slides Despite MAGiC Sweep Catheter FDA Submission

STXS submits MAGiC Sweep, the first robotically navigated high-density EP mapping catheter for FDA clearance, marking a milestone in cardiac arrhythmia treatment.

Zacks 3 months ago

STXS
-2.76%

BSX

CAH
STXS Stock Tumbles Despite EMAGIN Catheter Submission for Approval

Stereotaxis submits EMAGIN 5F, a robotic catheter, for regulatory clearance.

Zacks 3 months ago

STXS
-2.76%
Stereotaxis sees double digit revenue growth for FY25

Stereotaxis (STXS) anticipates double digit revenue growth for the full year 2025. Recurring revenue is expected to scale throughout the year, from $5 million in the first quarter to $7 million in the fourth quarter, as an expanded portfolio of catheters increasingly contributes to revenue. System revenue of $2-3 million per quarter is expected to remain approximately flat with 2024, with modest contributions from GenesisX in Europe and Genesis in China. Anticipated regulatory milestones and ini

TipRanks 3 months ago

STXS
-2.76%
Stereotaxis submits EMAGIN catheter for regulatory clearance

Stereotaxis (STXS) announced FDA regulatory submission for the first robotically navigated catheter designed to expand usage of Robotic Magnetic Navigation into the broader endovascular field. EMAGIN 5F is the first in a family of robotically navigated endovascular devices being developed by Stereotaxis. The EMAGIN brand – short for Endovascular Magnetic Intervention – will encompass a comprehensive portfolio of robotic catheters and wires. EMAGIN 5F is a catheter guide with a 5-French diameter

TipRanks 3 months ago

STXS
-2.76%
Stereotaxis announces FDA regulatory submission for MAGiC Sweep catheter

Stereotaxis (STXS) announced FDA regulatory submission for the MAGiC Sweep catheter. MAGiC Sweep is the first high-density EP mapping catheter developed to be robotically navigated using Stereotaxis’ Robotic Magnetic Navigation systems. “The development of the first ever robotically navigated high-density mapping catheter is a major milestone for the EP field,” said Dr. Roderick Tung, Chief of Cardiology and Director of Cardiovascular Clinical Research at The University of Arizona College of Med

TipRanks 3 months ago

STXS
-2.76%
Stereotaxis Inc (STXS) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amid Strategic ...

Stereotaxis Inc (STXS) reports a 39% increase in fourth-quarter revenue, driven by strategic innovations and key regulatory milestones.

GuruFocus.com 3 months ago

STXS
-2.76%
Stereotaxis Inc. (STXS) Reports Q4 Loss, Lags Revenue Estimates

Stereotaxis (STXS) delivered earnings and revenue surprises of -80% and 9.43%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 3 months ago

STXS
-2.76%

Performance Overview

Return	STXS	S&P 500 (^GSPC)
YTD	-7.46%	+1.62%
1-Year	+10.47%	+10.00%
3-Year	+4.98%	+59.40%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Stereotaxis, Inc. (STXS)

Stereotaxis Inc (STXS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst ...

Stereotaxis Inc. (STXS) Reports Q1 Loss, Tops Revenue Estimates

Stereotaxis Reports 2025 First Quarter Financial Results

AxoGen (AXGN) Reports Q1 Loss, Tops Revenue Estimates

Thermo Fisher Scientific (TMO) Q1 Earnings and Revenues Beat Estimates

Stereotaxis to Report First Quarter 2025 Financial Results on May 12, 2025

Stereotaxis to Feature First-Ever Live Demo of GenesisX Robotic System at HRS 2025

3 Promising Surgical Robotics Stocks to Keep an Eye on in 2025

Nvidia’s Support Boosts Stereotaxis (STXS) in Advancing Robotic Surgery

Stereotaxis Jumps 15% on NVIDIA's AI-Driven Collaboration: Is It a Buy Now?

March 2025 Penny Stocks With Promising Prospects

Stereotaxis Highlighted by NVIDIA at GTC Artificial Intelligence Conference and Accepted into NVIDIA Connect Program

Stereotaxis to Present at 37th Annual Roth Conference

Stereotaxis Stock Slides Despite MAGiC Sweep Catheter FDA Submission

STXS Stock Tumbles Despite EMAGIN Catheter Submission for Approval

Stereotaxis sees double digit revenue growth for FY25

Stereotaxis submits EMAGIN catheter for regulatory clearance

Stereotaxis announces FDA regulatory submission for MAGiC Sweep catheter

Stereotaxis Inc (STXS) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amid Strategic ...

Stereotaxis Inc. (STXS) Reports Q4 Loss, Lags Revenue Estimates

Performance Overview